• A microscopic image of cells from a tumor with uniform STAG2 expression
    For Some Bladder Cancer Patients, Simple Test Could Reduce Overtreatment, Ease High Cost

    A team of scientists led by Georgetown Lombardi Comprehensive Cancer Center researchers has published a study validating that a new test could be key to reducing the cost of caring for patients with bladder cancer while simultaneously relieving some patients of unnecessary treatment.

  • Dr. Weiner speaks at a glass podium in front of a display of sports memorabilia and a window
    Georgetown Lombardi Men's Event Boasts Another Year of Success

    Over 200 men gathered for the 19th annual Men’s Event, a fundraising dinner to raise awareness and money for research at Georgetown Lombardi Comprehensive Cancer Center on cancers that affect men.

  • Marc E. Lippman in a portrait shot in which he wears a white lab coat and tie
    Acclaimed Breast Oncologist/Researcher Returns to Georgetown’s Cancer Center

    Physician-scientist Marc E. Lippman, MD, MACP, FRCP, rejoins Georgetown Lombardi Comprehensive Cancer Center as a member of the breast cancer program and will also be a professor in the departments of oncology and medicine at Georgetown University Medical Center.

  • Carren Oler reciting her poem, Cancer’s Unwelcome Return and the Four Angels, and showcasing an illustration of the angels
    From Chapel to Coffeehouse

    The third annual Poetry Cafe, hosted by the Georgetown Lombardi Arts and Humanities Program and Mission & Pastoral Care on June 7 in the chapel at MedStar Georgetown University Hospital, provided the hospital community with the opportunity to collectively share their thoughts and experiences through poetry and more.

  • A microscopic image of breast cancer cells in color
    Exciting Research Finding Ushers in New Era in Breast Cancer Treatment

    Definitive results from a large international breast cancer study that included Georgetown Lombardi Comprehensive Cancer Center show that a genetic test can help determine the course of a woman’s treatment and will ultimately spare many women with the most common subtype of breast cancer from receiving chemotherapy.

  • Angela Ertlschweiger is pictured indoors near a window
    Inspiration and Celebration at the 13th-Annual Women & Wine

    The 13th-annual Women & Wine event, which took place on April 18, raised over $630,000 for the Nina Hyde Center for Breast Cancer Research at Georgetown Lombardi Comprehensive Cancer Center.

  • A man in a white coat is speaking
    Research in a Minute: Giuseppe Giaccone, MD, PhD

    As associate director of clinical research at Georgetown Lombardi Comprehensive Cancer Center and professor of medical oncology and pharmacology at Georgetown University School of Medicine, Giuseppe Giaccone, MD, PhD, leads a team of researchers in studying thymic carcinoma, also known as cancer of the thymus.

  • A brick sign for Frederick National Laboratory sits in a landscaped area outdoors
    Frederick National Laboratory and Georgetown Launch Research and Education Collaboration

    A new collaboration between Georgetown University and the Frederick National Laboratory for Cancer Research in Frederick, Maryland, aims to expand both institutions’ research and training missions in the biomedical sciences.

  • Image of the Georgetown University Medical and Dental building taken in the evening
    Family History Increases Breast Cancer Risk Even in Older Women: Weighing Screening Options

    Family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women ages 65 and older, according to research published by a team led by Dejana Braithwaite, PhD, associate professor of oncology at Georgetown University School of Medicine and a member of Georgetown Lombardi Comprehensive Cancer Center.

  • The Med-Dent building bathed in the fading light of day
    New Immunotherapy Combination Tolerable, Effective in Patients with Advanced Kidney Cancer

    A study led by Michael B. Atkins, MD, deputy director, Georgetown Lombardi Comprehensive Cancer Center, that combined an agent that blocks blood vessel formation with an immunotherapy agent was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer who had not been previously treated.